Anaplastic lymphoma kinase–rearranged lung adenocarcinoma (ALK + LUAD) is currently considered an immune-resistant disease, yet underlying biological mechanisms are largely unknown. In this issue, ...

Summary:. In this issue of Blood Cancer Discovery, Newman and colleagues investigated the impact of genetic ancestry on molecular subtypes, genomic alterations, and survival outcomes in a diverse ...

AbstractMyeloid cells are central players in innate immunity and inflammation. Their function is regulated by the adapter protein TRAF3. We previously reported that aging myeloid cell–specific ...

Abstract. We analyzed demographic trends among patients enrolled in National Cancer Institute Cancer Therapy Evaluation Program-sponsored early phase clinical trials in 2000–2023. Using a large ...

Abstract. On February 16, 2024, the FDA granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) indicated for the treatment of adult patients with unresectable or ...

The FDA today introduced FDA PreCheck, a new program aimed at reducing U.S. reliance on foreign drug manufacturing by simplifying the approval process for domestic manufacturing. The agency said it ...

Abstract. On August 11, 2023, the FDA approved the fixed-dose combination of niraparib and abiraterone acetate (AA), with prednisone (AAP), for the treatment of adult patients with deleterious or ...

A phase I study of the bispecific antibody–drug conjugate BL-B01D1 shows encouraging safety and effectiveness. The drug, which targets EGFR and HER3, triggered side effects in most patients, but at ...

AbstractBiliary tract cancers (BTC) are aggressive malignancies encompassing intrahepatic and extrahepatic cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma. Here, we report ...

Using 3D bioprinted constructs, this study reports that cancer-associated fibroblasts (CAFs) suppress antitumor immunity through close interactions with cancer cells, more so than by acting as ...

Summary:. This spotlight highlights a novel multimodal risk stratification model for patients with locally advanced non–small cell lung cancer undergoing chemoradiation, integrating mid-treatment ...

Summary:. Lu and colleagues identified profound microbial heterogeneity across individual tumor nodules in multifocal hepatocellular carcinoma, revealing that specific bacterial consortia enrich in ...